Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)

Subclass of:

536 - Organic compounds -- part of the class 532-570 series

536000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

536100110 - Carbohydrates or derivatives

536180700 - Nitrogen containing

536220100 - N-glycosides, polymers thereof, metal derivatives (e.g., nucleic acids, oligonucleotides, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
536240500 Nucleic acid expression inhibitors 135
536240300 Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA 58
536230500 Encodes an animal polypeptide 53
536230200 Encodes an enzyme 49
536230700 Encodes a microbial polypeptide 20
536230600 Encodes a plant polypeptide 15
536230400 Encodes a fusion protein 12
536240100 Non-coding sequences which control transcription or translation processes (e.g., promoters, operators, enhancers, ribosome binding sites, etc.) 11
536240200 Non-coding sequences having no known regulatory function which are adaptors or linkers for vector or gene contruction 1
20090118488High throughput genome sequencing on DNA arrays - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences using adaptors interspersed in target polynucleotides. The sequence information can be new, e.g. sequencing unknown nucleic acids, re-sequencing, or genotyping. The invention preferably includes methods for inserting a plurality of adaptors at spaced locations within a target polynucleotide or a fragment of a polynucleotide. Such adaptors may serve as platforms for interrogating adjacent sequences using various sequencing chemistries, such as those that identify nucleotides by primer extension, probe ligation, and the like. Encompassed in the invention are methods and compositions for the insertion of known adaptor sequences into target sequences, such that there is an interruption of contiguous target sequence with the adaptors. By sequencing both “upstream” and “downstream” of the adaptors, identification of entire target sequences may be accomplished.05-07-2009
Entries
DocumentTitleDate
20130030163METHOD FOR ISOLATING AND PURIFYING NUCLEIC ACIDS - The present invention relates to a method for isolating and purifying nucleic acids, preferably comprising genomic DNA, from biological samples comprising the steps of lysing the sample using a lysis buffer comprising a source of anionic surfactant ions, optionally disintegrating the RNA present in the lysate, precipitating the surfactant ions from the lysate, and separating the nucleic acids from the precipitate and further contaminants by size-exclusion chromatography. The invention furthermore relates to a lysis buffer, a method of lysing cells and a kit for the isolation and purification of nucleic acids.01-31-2013
20120172582Labelling Strategies for the Sensitive Detection of Analytes - The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.07-05-2012
20120184726SHORT RNA MIMETICS - The present invention provides synthetic oligonucleotides that mimic the function of short RNAs such as, for example, microRNAs or short interfering RNAs. In particular, the synthetic oligonucleotides comprise a duplex region comprising an unpaired bulge in one of the strands.07-19-2012
20120184725Nucleic Acid Purification - Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA.07-19-2012
20120184724PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS - A nucleoside monomer that is protected by a thionocarbamate protecting group and contains one or more 07-19-2012
20100160618Expanding the eukaryotic genetic code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.06-24-2010
20090192303NUCLEIC ACID EXTRACTION METHOD - The present invention relates to a method for isolating nucleic acids from a nucleic acid containing sample, and a kit for carrying out said method. More specifically, it relates to a novel method for extracting nucleic acids from a nucleic acid containing sample, using an anion exchange solid support, and allowing this solid phase with the nucleic acid bound thereto to react with a compound which is also capable of binding to said anion exchange solid support and which optionally provides additional charges at the surface of the anion exchange solid material, thereby preferably changing the surface charge density of the solid support and then releasing the nucleic acid from the solid support, eliminating the need for high salt and/or high pH elution buffers.07-30-2009
20110196142DNA molecule for expressing Hairpin RNA, the constructing method and the use thereof - DNA molecule for expressing hairpin RNA, the constructing method and the use thereof are provided. The DNA molecule is a closed single-strand cyclic DNA molecule which is constructed by linking four fragments A, B, C and D as following order: A-C-B-D or A-D-B-C, wherein A is a sense strand or anti-sense strand fragment of the target double-strand DNA; B is the fragment which is reversely complementary to A; C and D are DNA fragments with stem-loop structure and they meet one of the following requirements: 1) the nucleotide sequence of fragment C or D comprises at least one sequence e; 2) the nucleotide sequence of fragment C comprises at least one sequence e, the nucleotide sequence of fragment D comprises at least one sequence f, wherein sequences e and f individually are one strand of different restriction endonuclease recognition sequences. The DNA molecule for expressing hairpin RNA and its constructing method are useful in constructing lhRNA library.08-11-2011
20110196141LOCKED AND UNLOCKED 2'-O PHOSPHORAMIDITE NUCLEOSIDES, PROCESS OF PREPARATION THEREOF AND OLIGOMERS COMPRISING THE NUCLEOSIDES - The present invention relates to 2′-O-phosphoramidite of locked nucleoside and unlocked nucleoside, their synthesis and 2′-5′-linked oligomers oligomers comprising the nucleosides to delineate the structural requirements of 2′-5′ RNA/DNA: 3′-5′ RNA duplexes and also for use in antisense applications.08-11-2011
20100036104DETECTION OF NUCLEIC ACIDS BY TARGET-SPECIFIC HYBRID CAPTURE METHOD - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods.02-11-2010
20120208991BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE - It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity08-16-2012
20090156793Circular Chromosomes - Circular chromosomes with centromere DNA comprise recombination sites flanking a region with bacterial replication DNA and a recombinase transcription unit. Circular chromosomes without bacterial replication DNA are formed by removing bacterial replication DNA from a circular chromosome by action of a recombinase that excises DNA between said recombination sites.06-18-2009
20090156792BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present disclosure describes bis-modified bicyclic nucleosides and oligomeric compounds that can be prepared comprising at least one of these bis-modified bicyclic nucleosides. More particularly, the bis-modified bicyclic nucleosides have at least one substituent group at the 5′-methylene and on the bridge methylene and can be chiral. These bis-modified bicyclic nucleosides are expected to be useful for enhancing one or more property of oligomeric compounds including for example enhancing nuclease resistance.06-18-2009
20130046084OLIGONUCLEOTIDE LIGATION - Oligonucleotide chemistry is central to the advancement of core technologies such as DNA sequencing, forensic and genetic analysis and has impacted greatly on the discipline of molecular biology. Oligonucleotides and their analogues are essential tools in these areas. They are often produced by automated solid-phase phosphoramidite synthesis but it is difficult to synthesize long DNA and RNA sequences by this method. Methods are proposed for ligating oligonucleotides together, in particular the use of an azide-alkyne coupling reaction to ligate the backbones of oligonucleotides together to form longer oligonucleotides that can be synthesized using current phosphoramidite synthesis methods.02-21-2013
20090131644HERPESVIRUS RIBOZYMES AND VECTORS - Hammerhead ribozymes that target components critical to HSV replication (ICP4, U05-21-2009
20100331534 NUCLEIC ACID PURIFICATION METHOD - The invention provides an modified method for the separation of nucleic acids from cells, comprising: generating an aqueous solution containing the nucleic acid by lysing the cells with a lysis solution including SDS and salt; and separating the nucleic acids of interest from other cellular components. The improvement includes adding a non-ionic detergent in the lysis solution such that SDS is not precipitated and no heating of the solution is required prior to cellular lysis. The preferred non-ionic detergents are the polysorbate family of compound, including TWEEN® 20. Also disclosed are composition and kit for performing the modified method.12-30-2010
20100093985USE OF AT LEAST ONE CYTOSOLIC PHOSPHOLIPASE A2 INHIBITOR AS A MEDICINE FOR SYMPTOMATIC TREATMENT OF MUCOVISCIDOSIS - A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis.04-15-2010
20090124793Corticotropin releasing factor 2 receptor agonists - Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.05-14-2009
20130046083OLIGONUCLEOTIDE LIGATION - Oligonucleotide chemistry is central to the advancement of core technologies such as DNA sequencing, forensic and genetic analysis and has impacted greatly on the discipline of molecular biology. Oligonucleotides and their analogues are essential tools in these areas. They are often produced by automated solid-phase phosphoramidite synthesis but it is difficult to synthesize long DNA and RNA sequences by this method. Methods are proposed for ligating oligonucleotides together, in particular the use of an azide-alkyne coupling reaction to ligate the backbones of oligonucleotides together to form longer oligonucleotides than can be synthesized using current phosphoramidite synthesis methods.02-21-2013
20090118484FORMATION OF NOVEL NUCLEIC ACID COMPLEXES AND DETECTION THEREOF - This invention relates to a process and system to amplify and detect recombinational non-reciprocal cross-over reactions between homologous nucleic acid molecules without the assistance from a protein factor. The result of a chain reaction of non-reciprocal cross-overs is stoichiometrical formation of nucleic acid conglomerate complex that binds significantly more ethidium bromide or other fluorophores than a canonical B-form double helical nucleic acid does, emitting much stronger fluorescence. Such nucleic acid conglomerate complex can be easily detected by conventional methods, therefore can be used to detect any target molecule of interest.05-07-2009
20090093621Novel peptides comprising repetitive units of amino acids and DNA sequences encoding the same - Novel polypeptides comprising repetitive units of amino acids, as well as synthetic genes encoding the subject polypeptides are provided. The subject polypeptides are characterized by comprising repetitive units of amino acids, where the repetitive units are present in naturally occurring proteins, particularly naturally occurring structural proteins. The subject polypeptides find use in a variety of applications, such as structural components of prosthetic devices, synthetic fibers, and the like.04-09-2009
20130072670RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END - The present invention relates to novel phosphoramidites, A-n-bz, C-n-bz, C-n-ac, G-n-ac and U are produced with an HPLC purity of greater than 98% and 03-21-2013
20130072669Covalently Functionalized Carbon Nanostructures and Methods for Their Separation - The present invention is directed to carbon nanostructures, e.g., carbon nanotubes, methods of covalently functionalizing carbon nanostructures, and methods of separating and isolating covalently functionalized carbon. In some embodiments, carbon nanotubes are reacted with alkylating agents to provide water soluble covalently functionalized carbon nanotubes. In other embodiments, carbon nanotubes are reacted with a thermally-responsive agent and exposed to light in order to separate carbon nanotubes of a specific chirality from a mixture of carbon nanotubes.03-21-2013
20110015379METHOD AND KIT FOR PREPARATION OF SAMPLE FOR USE IN NUCLEIC ACID AMPLIFICATION - The object is to remove substances that can inhibit nucleic acid amplification from biological samples and nucleic acid extracts, and to allow convenient and accurate evaluation of the presence or absence of a target nucleic acid or the expression level of a target gene in a biological sample, by nucleic acid amplification means employing an enzyme. The invention provides a method for preparation of a sample for use in nucleic acid amplification, to be used for amplification of nucleic acid in a biological sample, which method comprises an extraction step in which a nucleic acid extraction reagent is added to the biological sample to obtain a nucleic acid extract, and a purification step in which the nucleic acid extract is contacted with zeolite to obtain a nucleic acid amplification sample suitable for nucleic acid amplification, to allow nucleic acid detection at high sensitivity.01-20-2011
20120190833METHOD OF SELECTION, BY TWO-DIMENSIONAL SEPARATION, OF NUCLEIC ACIDS THAT BIND TO A TARGET WITH HIGH AFFINITY - The invention relates to a method of selection, by two-dimensional separation, of nucleic acids that bind to a target molecule with high affinity from a mixture of nucleic acids, including the following steps: a) subjecting the mixture of nucleic acids to a physico-chemical separation step, thereby obtaining a set of mixed fractions containing the nucleic acids, a run parameter window being associated with every mixed fraction containing the nucleic acids, b) contacting a mixed fraction containing the nucleic acids with the target molecule, thereby obtaining a binding mixture containing nucleic acid/target molecule complexes, c) subjecting the binding mixture from step b) to the same physico-chemical separation step as in step a), thereby selecting nucleic acid/target molecule complexes whose run parameters are outside of the run parameter window.07-26-2012
20090299043Template-Synthesized DNA Nanotubes - A method of forming DNA nanotubes composed entirely or predominantly from DNA that, The methods of the present invention form single layer or multilayer template-synthesized nanotubes where the bulk of the tube is composed of DNA, and the layers are held together by hybridization of complementary DNA strands. The DNA molecules making up these tubes may be varied as desired, and the DNA is capable of being released from the tube.12-03-2009
20090270601Differential detection of single nucleotide polymorphisms - This application claims processes and compositions that enable discovery of single nucleotide polymorphisms (SNPs) and other sequence variation that follows two essentially identical sequences, one a reference, the other a target, as well as SNPs discovered using these processes and compositions. The inventive process comprises preparation of four sets of primers, “T-extendable”, “A-extendable”, “C-extendable”, and “G-extendable”. These primers, when templated on a reference genome, add (respectively) T, A, C, and G to their 3′-ends. The invention also comprises a step where these primer sets are separately bound to complementary sequences on target DNA and, once bound, prime extension reactions using target DNA as the template. If the target DNA directs incorporation of the same nucleotide as the reference DNA, then the T-, A-, C-, and G-extendable primers are extended (respectively) by T, A, C, and G. The architecture of the process distinguishes products from these extensions from products derived if not T, not A, not C and not G (“3N” or “3”, to indicate the other three nucleotides) are not added. Thus, this process discovers differences between the target and reference DNA in the site queried by the primer extension reaction. The distinction makes the two kinds of products either separable or differentially extendable. This distinction is used to disregard products that added T, A, C, and G and to identify the sequence(s) of primers that added not-T, not-A, not-C, and not-G. Further and optionally, information from these sequences identifies loci of the SNPs in an in silico genome.10-29-2009
20100069621POLYNUCLEOTIDES AND RELATED NANOASSEMBLIES, STRUCTURES, ARRANGEMENTS, METHODS AND SYSTEMS - A linker polynucleotide for attaching a nanomaterial to a polynucleotidic platform and related nanoassemblies, arrangements, structures, methods and systems.03-18-2010
200900122816-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.01-08-2009
20090012280OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS - A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5′ leader region of the positive-strand viral genome and negative-strand 3′ subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication.01-08-2009
20080207885Method for site-specific labeling of RNA using a deoxyribozyme - The present invention is a method for site-specific internal RNA modification. In accordance with the present method, a deoxyribozyme (DNA enzyme) is used as a catalyst to attach a tagging RNA to a pre-determined internal position of a target RNA molecule, wherein the tagging RNA is coupled to a label prior to or after attachment to the target RNA molecule thereby labeling the target RNA.08-28-2008
20090062520Method of producing DNA structure and DNA structure - The present invention provides a method of producing a DNA structure in which multiple quadruplex DNAs are linked, which includes (a) a step of mixing multiple DNA molecules having an antiparallel quadruplex structural part, and at least two single stranded sticky ends extended from the end of the quadruplex structural part, wherein the single stranded sticky end of the each DNA molecule has a base sequence that can form a duplex through interaction with the single stranded sticky end of other DNA molecule.03-05-2009
20110282043METHODS AND COMPOSITIONS COMPRISING NUCLEIC ACID POLYMERIZATION ENHANCERS - Embodiments of the invention are directed to compositions and methods that use non-extendable oligonucleotides to enhance or improve synthesis or amplification of nucleic acids.11-17-2011
20110288284METHODS AND COMPOSITIONS FOR ISOLATING POLYNUCLEOTIDES - Methods of isolating target double-stranded polynucleotides with internal single-stranded regions are provided. Compositions and kits comprising double-stranded polynucleotides with internal single-stranded regions are also provided11-24-2011
20110294995Functionalized nanoparticles and other particles and methods for making and using same - Disclosed are nanoparticles which include a nanoparticle core having a core diameter of greater than 5 nm and a single functional moiety bonded to the nanoparticle core. Also disclosed are nanoparticles which include a nanoparticle core having a core diameter of greater than 1.4 nm and a single functional moiety bonded to the nanoparticle core, wherein the single functional moiety does not contain a nucleic acid molecule that includes 100 or more nucleotides. A method for preparing a functionalized nanoparticle is also disclosed. The method includes providing a nanoparticle core and providing a functionalizing moiety that includes a functional group and a reactive group. The functional group is attached to a substrate surface, and the reactive group is capable of bonding to the nanoparticle core's surface. The method further includes contacting the nanoparticle core's surface with the functionalizing moiety under conditions effective to bind the functionalizing moiety's reactive group and the nanoparticle core's surface together.12-01-2011
20090062521AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID - To provide an excellent amidite for synthesizing modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid, and a method for synthesizing modified nucleic acid using the amidite. Specifically, an amidite for synthesizing modified nucleic acid, expressed by General Formula (I):03-05-2009
20110294996QUANTUM UNIT OF INHERITANCE - Quantum genes have a unique identifier assigned to them. By identifying genetic material with a unique identifier a means of locating specific genetic material is plausible. Delivering such quantum genes, that contain a unique identifier, to specific cell types provides a means of inserting specific genetic information into the cell's nuclear deoxyribonucleic acid that can be readily located by the cell's nuclear transcription complexes. These medically therapeutic quantum genes are intended to provide a wide variety of medical therapeutic options to clinicians.12-01-2011
20100036105RNA complexes, methods of their production - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same.02-11-2010
20100063265CORN EVENT 3272 AND METHODS OF DETECTION THEREOF - A novel transgenic corn event designated 3272, is disclosed. The invention relates to DNA sequences of the recombinant constructs inserted into the corn genome that resulted in the 3272 event and of genomic sequences flanking the insertion sites as well as to assays for detecting the presence of the 3272 event based on these novel sequences. The invention further relates to seeds of corn plants comprising the 3272 genotype, to corn plants comprising the genotype of 3272 and to methods for producing a corn plant by crossing a corn plant comprising the 3272 genotype with itself or another corn variety.03-11-2010
20100063264NUCLEOTIDE SEQUENCING VIA REPETITIVE SINGLE MOLECULE HYBRIDIZATION - Methods of obtaining sequence information about target oligonucleotides by repetitive single molecule hybridization are disclosed. The methods include exposing a target oligonucleotide to one or more copies of a test oligonucleotide; measuring hybridization; dehybridizing the test oligonucleotide; and repeating until the information content from the hybridization trials equals or exceeds the information content of the target oligonucleotide.03-11-2010
20090312532Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure - The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the binding of an SR protein and/or methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.12-17-2009
20120035353ALIGNED NANOSTRUCTURED POLYMERS - Novel, simple methods are presented directed to the synthesis of aligned nanofibers of polyaniline and substituted derivatives on a substrate. The production of these fibers is achieved via various methods by controlling the concentration of aniline monomer or substituted aniline derivatives or an oxidant in the reaction medium and maintaining said concentration at a level much lower than conventional polyaniline synthesis methods. Methods are disclosed relating to the use of a permeable membrane to control the release of a monomer and/or oxidant as well as a bulk polymerization method.02-09-2012
20090030189mTOR GLS and ELS, their small molecule mimetics and competitive inhibitors - The present invention relates generally to molecular mechanisms of mTOR-related human diseases. More specifically, the invention relates to two novel related polypeptides, the ER-localization sequence (ELS) and Golgi-localization sequence (GLS) along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.01-29-2009
20100137570HOST CELL PROTEIN KNOCK-OUT CELLS FOR PRODUCTION OF THERAPEUTIC PROTEINS - The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.06-03-2010
20090093622BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis - The invention provides BASB029 polypeptides and polynucleotides encoding BASB029 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.04-09-2009
20090023905Transgenic animal model of bone mass modulation - The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.01-22-2009
20100081801Method for determining an unknown PNA sequence and uses thereof - The invention relates to a method for determining an unknown PNA sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with one or several different nucleic acid molecule species comprising nucleic acid molecules with at least one nucleotide, wherein the nucleic acid molecules at least partially comprise a nucleic acid sequence that is complementary to at least a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the nucleic acid/PNA hybrids, wherein thereafter the nucleic acid/PNA hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence, and wherein the hybrid sequence information is optionally translated into the complementary PNA sequence information, and to a method for producing PNA molecules using such a process.04-01-2010
20100125134METHOD OF SEPARATING GENOMIC DNA AND PLASMID DNA FROM EACH OTHER AND KIT THEREFOR - Provided are a method of separating genome DNA and plasmid DNA from each other from a sample using a binding buffer containing a high concentration kosmotropic salt and chaotropic salt, and a kit therefor.05-20-2010
20100099858Maximizing Oligonucleotide Loading on Gold Nanoparticle - Increasing the amount of DNA loaded onto gold nanoparticles is disclosed. More particularly, methods of maximizing DNA loading, using salting techniques, sonication, temperature and other such procedures are disclosed.04-22-2010
20110172404Self-Assembly of Nanoparticles Through Nuclei Acid Engineering - A self-assembly nanodevice formed through nucleic acid engineering is disclosed. The nanodevice may include an array of nanoparticles. The nanodevice may further include a substrate that supports the array of nanoparticles. Each of the nanoparticles may be coordinated with a plurality of nucleic acids that are substantially free of Watson-Crick base-paring with nucleic acids coordinated with other nanoparticles. Methods of forming the nanodevice, as well as the microscopic organization of the nanoparticles are also disclosed. By manipulating the nucleic acids as capping ligands, the inter-particle distance may be extended to a greater range than nanotechnology based on alkyl ligands or nucleic acids base-pairing.07-14-2011
20110172403Microfluidic Device Including Purification Column with Excess Diluent and Method - Methods, apparatus, and a system are provided for processing a sample in a fluidic device. The device can include a purification column, an entrance opening to the purification column, an output reservoir, a fluid communication between the purification column and the output reservoir, and an openable and recloseable valve capable of interrupting fluid flow through the fluid communication. Methods of processing samples using such a device are also provided.07-14-2011
20090286969Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.11-19-2009
20110172405METHOD FOR SMALL RNA ISOLATION - This invention relates to a simple and rapid method for the extraction and purification of small RNA from a sample solution. Accordingly, a sample is first mixed with an organic solvent to form a mixture containing the solvent. The mixture is applied to a first mineral support for large RNA to bind. The filtrate is collected which contain unbound small RNA, and is mixed with a second organic solvent to form a second mixture containing the second solvent. This second mixture is applied to a second mineral support for small RNA to bind. After a wash step, the small RNA is eluted. Also provided is a method for the isolation of large RNA, by eluting the large RNA from the first mineral support. In addition, total protein is present in the filtrate and can be isolated by a conventional method.07-14-2011
20100286380PRETREATMENT METHOD FOR EXTRACTION OF NUCLEIC ACID FROM BIOLOGICAL SAMPLES AND KITS THEREFOR - The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.11-11-2010
20090043082MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.02-12-2009
20100113758METHOD FOR PURIFYING BIOMOLECULES - The present invention relates to a process for the purification of biomolecules, in particular of nucleic acids, such as DNA and RNA molecules.05-06-2010
20110269948Method for Identifying Compounds for Cancer Therapy - The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression.11-03-2011
20090082554Thiocarbonate linkers for polynucleotides - In various embodiments of the invention, novel compositions having a polynucleotide bound to a substrate via a cleavable linker are provided, and methods of cleaving a polynucleotide from a substrate are provided.03-26-2009
20090118485OLIGONUCLEOTIDES AND ANALOGS LABELED WITH ENERGY TRANSFER DYES - Novel linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye are provided. These linkers faciliate the efficient transfer of energy between a donor and acceptor dye in an energy transfer dye. One of these linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye has the general structure R05-07-2009
20090326209Method for isolating and modifying DNA from blood and body fluids - This invention is related a method for rapidly isolating and modifying DNA from plasma/serum and body fluids. This invention provides a procedure and composition to obtain a high yield of modified DNA for methylation-specific PCR assay by coupling DNA isolation and modification courses.12-31-2009
20090023906DRIED OLIGONUCLEOTIDE COMPOSITION AND METHOD OF PRODUCING THE SAME - The present invention relates to a dried oligonucleotide composition and a method for producing the same. More specifically, it relates to a dried oligonucleotide composition produced by the steps comprising adding a substance for preventing the oligonucleotide from being separated and lost, which is adhesive to a storage container containing the oligonucleotide composition, in order to prevent the oligonucleotide from being separated and lost during manufacturing and distributing the dried oligonucleotide composition, optionally adding a non-reactive dye substance, and drying the resulting solution. The dried oligonucleotide composition of the present invention can be prevented from being separated and lost during manufacturing step, or transporting step after packaging, and the presence or absence of the oligonucleotide in the storage container can be easily confirmed with naked eyes. Accordingly, unnecessary labor waste and time waste caused by the separation of the oligonucleotide upon experiment can be overcome.01-22-2009
200901980472'-Modified Oligonucleotides - Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.08-06-2009
20090209748OLIGONUCLEOTIDES WITH ALTERNATING SEGMENTS OF LOCKED AND NON-LOCKED NUCLEOTIDES - The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy.08-20-2009
20090203890HEPATITIS C ANTIVIRALS - The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases.08-13-2009
20090118483Light-driven energy generation using proteorhodopsin - A light-driven energy generation system using proteorhodopsin is provided. The system includes a light source, a host with a correctly folded, integrated proteorhodopsin protein, a source of retinal, and a mediator. The source of retinal binds covalently to the integrated proteorhodopsin protein, thereby creating a light absorbing pigment. Illumination of the light absorbing pigment with the light source results in conversion of light energy to biochemical energy. This biochemical energy is harnessed by the mediator to produce light-driven energy, such as mechanical, chemical or electrical energy.05-07-2009
200902218072' Deoxy-2'-Alkylnucleotide Containing Nucleic Acid - 2′-deoxy-2′-alkylnucleotides useful for stabilizing enzymatic nucleic acid molecules and antisense molecules.09-03-2009
20110230653STABILIZATION OF NUCLEIC ACIDS ON SOLID SUPPORTS - The present invention provides methods, compositions, and kits for the storage and stabilization of biological molecules. The methods comprise applying Tris(2-carboxyethyl)phosphine (TCEP) to at least one biological molecule bound to a solid substrate and storing in an organic solvent. Preferably, the biological molecules are nucleic acids. Compositions and kits for performing the process according to the invention are also provided.09-22-2011
20090259031CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS - The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.10-15-2009
20090253901Nanoencapsulation and Release of Nucleic Acids - A method for Encapsulation of nucleic acids such as DNA, RNA any other types of nucleotides via entrapping or co-precipitation in CaCO3 porous microparticles followed by polymeric shell deposition or polymer nanoparticles composite shell deposition. This method can be used for controlled delivery and release of nucleic acids.10-08-2009
20100160617NUCLEASE-RESISTANT RNA APTAMER INHIBITING REPLICATION OF HEPATITIS C VIRUS REPLICON - Disclosed a nuclease-resistant RNA aptamer for inhibiting the replication of HCV replicon. This aptamer is capable of binding specifically to HCV NS5B and inhibiting the proliferation of the HCV replicon, and is composed of at least one sequence selected from a group consisting of SEQ ID NOS. 1 to 4, in which a fluoro group is substituted for 2′-hydroxy of both U (uracil) and C (cytosine) bases, and SEQ ID NO. 4, which is tagged with a cholesteryl group at a 5′ end and with idT at a 3′ end. The RNA aptamer is useful in the diagnosis and treatment of HCV infection.06-24-2010
20100152431COMPOSITIONS, PROBES AND CONJUGATES AND USES THEREOF - The present invention relates to compositions useful as probes and in other applications and methods of their use. In some embodiments, nucleotides are prepared and functionalized with dyes. In some embodiments a first molecule is functionalized with an alkynyl group, a second molecule is functionalized with an azide group, and said first and second molecules are mixed under conditions to form a conjugate with a 1,2,3-triazol group. In further embodiments, a nucleotide is functionalized with an alkynyl group, a dye is functionalized with an azide group, and mixing the nucleotide and the dye forms a conjugate capable of emitting light.06-17-2010
20100261891NUCLEIC ACID ANCHORING SYSTEM COMPRISING COVALENT LINKAGE OF AN OLIGONUCLEOTIDE TO A SOLID SUPPORT - The anchoring system generally comprises a solid support and a chemical linking moiety useful for ether formation with another chemical moiety on a nucleic acid molecule. The present invention further contemplates methods for anchoring a nucleic acid molecule to a solid support via a covalent linkage. The anchoring system of the present invention is useful inter alia in construction of nucleic acid arrays, to purify nucleic acid molecules and to anchor nucleic acid molecules so that they can be used as templates for in vitro transcription and/or translation experiments and to participate in amplification reactions. The present invention is particularly adaptable for use with microspheres and the preparation of microsphere suspension arrays and optical fiber arrays. The anchoring system permits the generation of an anchored oligonucleotide for use as a universal nucleic acid conjugation substrate for any nucleic acid molecule or population of nucleic acid molecules. The present invention further provides a kit useful for anchoring nucleic acid molecules or comprising nucleic acid molecules already anchored to a solid support.10-14-2010
20090048434Compositions and methods relating to orthogonal ribosome mRNA pairs - Orthogonal ribosome orthogonal mRNA pairs are provided, as are methods for their selection involving a novel positive-negative selection approach, and methods for their use. Also provided are cellular logic circuits involving orthogonal ribosomes.02-19-2009
201001849665'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.07-22-2010
20100261890METHOD FOR THE CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES - The present invention features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof.10-14-2010
20100190970GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer.07-29-2010
20110060137STOOL SAMPLE PROCESSING METHOD AND STOOL SAMPLE PROCESSING CONTAINER - The present invention relates to a stool sample processing method and stool sample processing container the a stool sample processing container provided with a stool collection tool, a suspending solution holding portion and a processing solution holding portion, wherein stool sample preparation solutions consisting of a suspending solution and a stool sample processing solution are respectively housed in a suspending solution holding container and a processing solution holding container, after first mixing a stool sample with the suspending solution and suspending therein, a sealant is released into the suspending solution holding container by pressing on the lower portion of the processing solution holding container, and the resulting stool suspension mixes with the stool sample processing solution that stabilizes the nucleic acid.03-10-2011
20110060135Selective Purification of Small RNAs from Mixtures - Methods and kits are provided for obtaining small RNAs from a mixture of RNAs of varying sizes such as can be found in a cell lysate or an enzyme-digested RNA. The methods and kits utilize magnetic beads and require the addition of one or more alcohols to bind small RNAs effectively to the beads.03-10-2011
20130123482NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF - Nucleotide and/or oligonucleotide represented by formula (1) and the liquid phase synthesis process thereof. The present invention provides a liquid phase synthesis process for preparing a nucleotide and/or an oligonucleotide, comprising a process for combining the nucleotide and/or oligonucleotide protective groups, in which, under the condition that the 2′-hydroxyl group is protected by a group with a sterically hindered silane structure, the 3′ phosphate group(s) of the nucleotide and/or oligonucleotide is/are directly protected by (a)β-cyanoethyl group(s), and after the β-cyanoethyl group(s) is/are removed, the resulting product can directly participate in the next cycle of synthesis, wherein the synthesis reaction is carried out in a reaction flask or reaction kettle, without being limited by a solid carrier or synthesizer, so that the large scale preparation of oligonucleotides can be achieved.05-16-2013
20080207883Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.08-28-2008
20090111976Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same - Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.04-30-2009
20090043083METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.02-12-2009
20100222559NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO RABBIT-DERIVED lgG ANTIBODY - The present invention provides a nucleic acid molecule having an ability to bind to a rabbit anti-mouse IgG antibody, which can be prepared more easily than an antibody and has a binding ability equal to or higher than that of an antibody. The nucleic acid molecule according to the present invention may have the sequences set forth in SEQ ID NOS: 1 to 5. The nucleic acid molecule according to the present invention may be a nucleic acid having an ability to bind to a rabbit IgG antibody, which substantially has homology to its sequence. The nucleic acid molecule according to the present invention may have a binding constant (K09-02-2010
20110028703METHOD AND APPARATUS FOR SUSPENDING MAGNETIC MICROPARTICLES - A method includes applying ultrasound to a container having a plurality of magnetic particles contacted with a fluid sample having a biological material capable of binding to the magnetic particles, in an amount effective to suspend the magnetic particles in the fluid.02-03-2011
20100197899SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY - The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improvise the pharmacokinetic properties of the oligonucleotide. The aralkyl ligands of the present invention include naproxen, ibuprofen, and derivatives thereof. The present invention also provides method for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.08-05-2010
20100197900MODULATORS OF COAGULATION FACTORS - The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.08-05-2010
20090326208Methods and compositions for generating recombinant nucleic acid molecules - A method of generating a double stranded (ds) recombinant nucleic acid molecule covalently linked in both strands by contacting two or more ds nucleotide sequences with a topoisomerase under conditions such that both termini of at least one end of a first ds nucleotide sequence are covalently linked by the topoisomerase to both termini of at least one end of a second ds nucleotide sequence is provided. Also provided is a method for generating a ds recombinant nucleic acid molecule covalently linked in one strand, by contacting two or more ds nucleotide sequences with a type IA topoisomerase under conditions such that one strand, but not both strands, of one or both ends of a first ds nucleotide sequence are covalently linked by the topoisomerase. Compositions for performing such methods, and compositions generated from such methods also are provided, as are kits containing components useful for conveniently practicing the methods.12-31-2009
20090318676OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE - One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.12-24-2009
20090149640NUCLEIC ACID LADDERS - The present invention provides nucleic acid molecules which may be used as standards for estimating the size (in base pairs) and mass of linear, double-stranded or single-stranded nucleic acid molecules separated by size. The nucleic acid molecules of the invention may be DNA molecules, RNA molecules or DNA/RNA hybrid molecules, and may be double-stranded or single-stranded. The invention also provides methods for producing nucleic acid sizing ladders from these nucleic acid molecules, ladders produced by such methods, and methods for estimating the size and mass of nucleic acid molecules by comparison to these nucleic acid sizing ladders.06-11-2009
20100298552EMULSION COMPOSITIONS - An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system.11-25-2010
20100311957Families of Non-Cross-Hybridizing Polynucleotides for Use as Tags and Tag Complements, Manufacture and Use Thereof - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.12-09-2010
20100311958CARRIER, METHOD AND REAGENT FOR OBTAINING SMALL RNA - An object of the present invention is to provide a carrier which enables to obtain a small RNA in high yield yet in high purity, a simple method for obtaining a small RNA and/or a target nucleic acid of small RNA using the same, and a reagent and a kit comprising the above-described carrier.12-09-2010
20110034680MICROGININ PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AS WELL AS METHODS FOR CREATING NOVEL MICROGININS - The invention provides for nucleic acid molecules enabling the synthesis of microginin and microginin analogues. The invention also provides for methods for identifying microginins as well creating microginins which may not be found in nature.02-10-2011
20110118454METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED - The invention concerns a method for preparing monomer nucleotides or nucleotide analogues comprising the steps of: (1) coupling a soluble polyethylene glycol support provided with at least one diacid or ether-acid linker and a monomer nucleoside or nucleoside analogue to an amine group or hydroxyl group of the nucleoside with the aid of a coupling agent; (2) at least one step for phosphorylation of said nucleoside or nucleoside analogue coupled to said support with a phosphorylation agent; (3) cleavage of said support and recovery of at least one monomer nucleotide or nucleotide analogue. The nucleotides prepared are biological tools.05-19-2011
20110124852MOLECULAR MARKERS FOR IDENTIFICATION OF FAT AND LEAN PHENOTYPES IN CHICKENS - The invention provides molecular methods of screening chickens to determine those more likely to have a lean or fat phenotype by identifying the presence of at least one polymorphism in genetic material of a chicken in the thyroid hormone repressible gene (THRG) or its 3′ untranslated region (SEQ ID NO: 1) that is associated with a fat phenotype or a lean phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. The invention further provides oligonucleotide probes and primers useful for detecting the polymorphisms associated with a fat or lean phenotype.05-26-2011
20110087013Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones - The present invention concerns a synthesis process comprising the following steps (i) reacting 3-ethyl-4-nitrobenzoic acid with thionyl chloride to produce a 3-ethyl-4-nitrobenzoic acid chloride or a 3-ethyl-4-nitrobenzoic acid anhydride from 3-ethyl-4-nitrobenzoic acid by means of water cleavage and (ii) Friedel-Crafts acylation by reacting the 3-ethyl-4-nitrobenzoic acid chloride or the 3-ethyl-4-nitrobenzoic acid anhydride with an optionally substituted aryl-H to form an optionally substituted (3-ethyl-4-nitrophenyl)-aryl-methanone. In addition the present invention concerns compounds containing (3-ethyl-4-nitrophenyl)-aryl-methanone, characterized in that the optionally substituted aryl is an optionally substituted condensed aromate.04-14-2011
20100222560UNIVERSAL COLUMN - A universal column is provided which allows purification methods utilizing centrifugation, syringe coupling and/or use of a vacuum source. Methods for using the universal column and kits comprising the universal column are described.09-02-2010
20110124851Method of Isolation of Nucleic Acids - A method of isolation of nucleic acids from a biological sample of cells comprising a combination of a solid phase cell nuclei isolation procedure with a solid phase nucleic acid isolation method.05-26-2011
20110245479Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.10-06-2011
20090036660Methods and compositions for generating mixtures of nucleic acid molecules - In some embodiments, the present disclosure provides methods of making a mixture of nucleic acid molecules, the methods comprising the steps of: synthesizing on a substrate a population of nucleic acid molecules wherein each synthesized nucleic acid molecule comprises a substrate-attached proximal nucleic acid molecule, a distal nucleic acid molecule, and a cleavable linker linking the proximal nucleic acid molecule to the distal nucleic acid molecule, and harvesting distal nucleic acid molecules from the substrate by cleaving the cleavable linker under conditions that do not release the proximal nucleic acid molecule. Related compositions and kits are also provided.02-05-2009
20120245337NUCLEIC ACID PURIFICATION METHOD - The present intimation relates to a method for purifying nucleic acids from a sample containing nucleic acids, the method comprising at least the following steps: a. bringing the sample containing nucleic acids into contact with a nucleic acid binding phase comprising protonatable groups, wherein the protonatable groups have a pKa value of 9 to 12; b. binding the nucleic acids to the nucleic acid phase at a pH (binding pH) that is at least one pH unit less than the pKa value of at least one of the protonatable groups; c. eluting the nucleic acids at a pH greater than the binding pH but at least one pH unit less than the pKa value of at least one of the protonatable groups. Also disclosed are corresponding kits and nucleic acid binding phases that can be used for purifying nucleic acids.09-27-2012
20100069620NOVEL COMPOSITIONS OF CHEMICALLY MODIFIED SMALL INTERFERING RNA - The present invention is directed to compositions comprising chemically modified siRNA that have high specificity by virtue of no or insignificant off-target activity of the sense strand, no or insignificant induction of IFN-like responses, high potency to offset oligonucleotide manufacturing costs, favorable manufacturing chemistry, and effective means of intracellular delivery both in vitro, during target validation and model studies, and in vivo, during animal model studies and clinical trials in humans.03-18-2010
20110098457METHODS OF ATTACHING BIOLOGICAL COMPOUNDS TO SOLID SUPPORTS USING TRIAZINE - Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.04-28-2011
20110098456IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES - The invention relates to oligonucleotides including at least one FANA substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof.04-28-2011
20110060136DENDRIMER-COATED MAGNETIC FINE PARTICLES, AND METHOD FOR PREPARING SAME AND UTILITY THEREOF - Dendrimer-coated magnetic fine particles comprise magnetic fine particles, a lipid bilayer covering a surface of individual magnetic fine particles, and a dendrimer bound to an outer layer of the lipid bilayer. With the dendrimer-coated magnetic fine particles, the dendrimer is positively charged are brought into contact with a nucleic acid-containing solution to adsorb the nucleic acid on the dendrimer, while the nucleic acid-adsorbed fine particles are collected by magnetic force to recover the nucleic acid from the solution.03-10-2011
20100331532Use Of N-Alkyl Imidazole For Sulfurization Of Oligonucleotides With An Acetyl Disulfide - A method and compositions for sulfurizing at least one phosphite or thiophosphite linkage in an oligonucleotide. The addition of N-alkyl imidazole to the acetyldisulfide sulfurization solution enables the use of industrially preferred solvents or solvents that are derived from renewable resources.12-30-2010
20090018319DNA sequence in plant Caragana jubata with freeze tolerance - Abstract An isolated DNA sequence set forth in SEQ ID NO: 32, which is differentially expressed in apical buds of plant 01-15-2009
20100113759PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS - The present teachings relate to nucleobase, nucleoside and nucleotide compounds, methods of synthesis, and uses thereof. The present teachings provide compounds, such as nucleobase, nucleoside and/or nucleotide compounds including a propargyl linker, and methods for making or using such compounds.05-06-2010
20110152510SIMPLE LOAD AND ELUTE PROCESS FOR PURIFICATION OF GENOMIC DNA - Provided is a novel two step chromatographic purification process (load and elute) for the isolation of genomic DNA. In this method the sample is loaded on the column and the genomic DNA product is eluted directly without any intermediate wash steps. This is accomplished by utilizing a restricted access resin (i.e., lid beads), which is easy to prepare and comprised of two layers with different properties with non-functional surfaces on the outer layer. The inner layer is modified with functional groups that act as ion-exchangers. Small molecules such as RNA and proteins can enter the inner part of the resin and larger genomic DNA molecules will pass through the resin. RNA and proteins are captured in the inner layer of the restricted access resin while genomic DNA is readily eluted in the flow-through.06-23-2011
20120202981NOVEL GUANOSINE-RICH MODIFIED OLIGONUCLEOTIDES AND ANTIPROLIFERATIVE ACTIVITY THEREOF - The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.08-09-2012
20110178281Photocleavable Linker Methods and Compositions - Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos.07-21-2011
20110257383RNA COMPLEXES, METHODS OF THEIR PRODUCTION - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same.10-20-2011
20080207884siRNA targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to ATIC.08-28-2008
20110015380Systems, Compositions And Methods For Nucleic Acid Detection - The invention relates to stretch measurements of nucleic acids and correlating those measurements to the extent of double- and single-stranded content of a nucleic acid of interest, and to compositions, systems, and devices related thereto. In preferred embodiments, one performs the stretch or elasticity measurements under conditions such that one can determine a nucleic acid sequence or the presence of an oligonucleotide in a sample.01-20-2011
20110257382Nucleic acid separation using immobilized metal affinity chromatography - An immobilized metal affinity chromatography (IMAC) method for separating and/or purifying compounds containing a non-shielded purine or pyrimidine moiety or group such as nucleic acid, presumably through interaction with the abundant aromatic nitrogen atoms in the purine or pyrimidine moiety. The method can also be used to purify compounds containing purine or pyrimidine moieties where the purine and pyrimidine moieties are shielded from interaction with the column matrix from compounds containing a non-shielded purine or pyrimidine moiety or group. Thus, double-stranded plasmid and genomic DNA, which has no low binding affinity can be easily separated from RNA and/or oligonucleotides which bind strongly to metal-charged chelating matrices. IMAC columns clarify plasmid DNA from bacterial alkaline lysates, purify a ribozyme, and remove primers and other contaminants from PCR reactions. The metal ion affinity of yeast RNA decreases in the order: copper (II), nickel (II), zinc (II), and cobalt (II).10-20-2011
20110054157METHODS OF OPTIMAL PURIFICATION OF NUCLEIC ACIDS AND KIT FOR USE IN PERFORMING SUCH METHODS - A method and kit which allow the use of a discrete amount of a binding matrix to first purify nucleic acids from a medium under a first set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially independent of the amount of surface area of the definable amount of the binding matrix, followed by a second purification step wherein the nucleic acids are bound to a discrete amount of binding matrix under a second set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially dependent on the amount of surface area of the definable amount of the binding matrix, thus providing a discrete quantity of nucleic acid.03-03-2011
20110087014Process for the manufacture of oligonucleotides - A process for manufacturing an oligonucleotide which comprises removing β-eliminating phosphorus-protecting groups, in particular β-cyanoethyl protective groups from a protected oligonucleotide, wherein said removing comprises contacting the protected oligonucleotide with an amine solution in a solvent which preferably does not consist of pyridine, wherein the conjugate acid of the amine has preferably a pKa of greater than 11.5, and wherein the concentration of the amine in the solution is less than 0.5 mole/liters.04-14-2011
20100168408COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for to fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics.07-01-2010
20090171075Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo - Preparations of novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on a dendrimeric scaffold having a triazine core.07-02-2009
20110190483Stimulus-Responsive Apta Chelamers - Disclosed are apta-chelamers comprising aptamer domains tethered to rationally designed synthetic protein-binding modules, and methods of designing and making the same. Also disclosed are stimulus-responsive apta-chelamers capable of simultaneously or sequentially binding (and, thus, inhibiting) two protein targets.08-04-2011
20110190482POLYMER ENCAPSULATED ALUMINUM PARTICULATES - The present invention relates to use of novel bioinformatics approach for predicting and identifying Scaffold/Matrix attachment regions (S/MARs) from different genomic database.08-04-2011
20110201797Nucleic Acid Shearing Device with Disposable Cartridge - Apparatus, devices, and methods for shearing nucleic acids are provided. In one exemplary embodiment the device is a disposable nucleic acid shearing cartridge. The cartridge includes two reservoirs, an orifice structure disposed therebetween, and a fluid driver. The reservoirs are in fluid communication with each other by way of the orifice structure, and the fluid driver cycles a sample between the two reservoirs. By passing a sample from one reservoir to the next, through the orifice structure, an orifice located in the orifice structure can shear the sample to a desired length. The sheared sample can then be used, for example, in a sequencing device. Apparatuses for cycling samples in the cartridge, and methods and kits for shearing nucleic acids, are also disclosed.08-18-2011
20110201796DNA sequence in plant caragana jubata with freeze tolerance - An isolated DNA sequence set forth in SEQ ID NO: 32, which is differentially expressed in apical buds of plant 08-18-2011
20100029921Trioxyethylene Gold Nanoclusters Functionalized with a Single DNA - A method of making a nanoclusters functionalized with a single DNA strand comprising the steps of providing nanoclusters, combining said nanoclusters with thiolated DNA, incubating said nanoclusters and thiolated DNA mixture, combining said mixture with a solution comprising ethanol and dichloromethane; separating said mixture into an aqueous phase and an organic phase, mixing said aqueous phase with a solution comprising dicholormethane and NaCl, and separating the mixture into an aqueous phase and an organic phase; wherein said organic phase comprises said nanoclusters functionalized with a single DNA strand. Further, provided is a nanocluster functionalized with a single DNA strand comprising a nanocluster, said nanocluster being functionalized with a single DNA strand, said DNA strand having a length of about 10 to about 50 bases.02-04-2010
20100029920METHOD FOR ASSESSING THE EFFECT OF A DRUG ON LONG TERM MEMORY FORMATION - Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed.02-04-2010
20100022761PHOTOCLEAVABLE LINKER METHODS AND COMPOSITIONS - Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos.01-28-2010
20100016567PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE - A di(pyrimidine nucleoside 5′-)polyphosphate is synthesized by converting a pyrimidine nucleoside 5′-triphosphate into a pyrimidine nucleoside 5′-cyclic triphosphate by use of a condensing agent, and subsequently reacting the pyrimidine nucleoside 5′-cyclic triphosphate with a pyrimidine nucleotide in the presence of a salt of a metal selected from among magnesium, manganese, and iron.01-21-2010
20100016569CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip.01-21-2010
20100016566Method of synthesizing cdna and method of synthesizing rna chains, and nucleotide-immobilized carrier - A method of synthesizing a cDNA chain using an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a group derived from a phosphoric ester composing the hydrophilic portion of phospholipid, and a second unit having a group derived from carboxylic acid having an electron-attractive substituent bound to a carbonyl group, which includes immobilizing a polynucleotide for DNA elongation; bringing a solution containing an RNA fragment, nucleotide monomers, and a reverse transcriptase or an enzyme having polymerase activity into contact with the surface of the insoluble carrier; and allowing the polynucleotide for DNA elongation immobilized on the surface of the carrier to elongate using the RNA fragment contained in the solution as a template, to thereby form a single-strand cDNA.01-21-2010
20080262210Immunostimulating Agents - Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having β-1,3-bonds (preferably β-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.10-23-2008
20100331533Use Of Thioacetic Acid Derivatives In The Sulfurization Of Oligonucleotides With Phenylacetyl Disulfide - A method and compositions for sulfurizing at least one phosphite or thiophosphite linkage in an oligonucleotide. The methods employ a phenylacetyl disulfide reagent (known as PADS), phenylthioacetic acid (PTAA) in the presence or absence or N-alkyl imidazole in industrially preferred solvents or solvents that are derived from renewable resources. The use of PTAA eliminates the need to “age” the PADS solution prior to its use in sulfurization reactions.12-30-2010
20100286377BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE - Methods of binding biomolecules to a substrate are provided that include contacting the biomolecule with a branched linking moiety to form a branched linking structure. The branched linking structure is then contacted with a binding moiety on the substrate to form a coupled substrate binding structure, thereby binding the biomolecule to the substrate. The biomolecule may contain a Lewis base or a nucleophile to react with a Lewis acid or electrophile in the branched linking moiety. Alternatively, the biomolecule may contain a Lewis acid or electrophile that can react with a Lewis base or nucleophile in the branched linking moiety. Additionally, the biomolecule can be bound to the substrate through a covalent or non-covalent bond.11-11-2010
20100016568CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip.01-21-2010
20110046359REVERSIBLE TERMINATOR NUCLEOTIDES AND METHODS OF USE - Disclosed herein a reversible terminator nucleotides and methods of use.02-24-2011
20130012693Aptamers to Beta-NGF and Their Use in Treating Beta-NGF Mediated Diseases and Disorders - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to β-NGF; pharmaceutical compositions comprising such β-NGF aptamers; and methods of making and using the same.01-10-2013
20110306758METHOD AND MATERIALS FOR THE COOPERATIVE HYBRIDIZATION OF OLIGONUCLEOTIDES - A two-stranded intermediary complex and cooperative hybridization method are provided. The complex has been designed so that target oligonucleotides of independent sequence can cooperatively and simultaneously hybridize to it. The cooperative hybridization mechanism is robust and modular, smoothly integrating with other dynamic DNA components to form cascaded reaction networks that can perform a variety of functions.12-15-2011
20110082286Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.04-07-2011
20120283423APPARATUS, SYSTEM AND METHOD FOR PURIFYING NUCLEIC ACIDS - Methods and devices for isolating nucleic acids from a mixture containing such nucleic acids and extraneous matter are provided. In one embodiment, the method of the invention comprises passing the mixture through a glass frit under conditions effective to separate the nucleic acids from the extraneous matter. In a more specific embodiment, the glass frit is a sintered glass frit.11-08-2012
20090216003STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA - The present invention describes a flexible basestacking monomer that can be incorporated into an oligonucleotide or oligonucleotide analogue, as well as triplex forming oligonucleotides comprising the flexible basestacking monomer. Triplex forming oligonucleotides of the invention are capable of binding sequence specifically to doublestranded target nucleic acids and are therefore of interest for modulation of the activity of target nucleic acids and also detection of target nucleic acids.08-27-2009
20120208990HUMAN PLATELET F11 RECEPTOR - The present invention is directed to isolated nucleic acid molecules encoding human platelet F11 receptors. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of the human platelet F11 receptor in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify human platelet F11 receptor function, and a method for isolating other human platelet F11 receptor molecules. DNA oligomers capable of hybridizing to the nucleic acid molecule encoding the human platelet F11 receptor are provided, which can be used to detect human platelet F11 receptor in a sample.08-16-2012
20120010392PROTEIN KINASE-INDUCIBLE DOMAINS - Applicants have used protein design to develop novel functional protein architectures, termed protein kinase-inducible domains, whose structures are dependent on phosphorylation by specific protein kinases or are dependent on dephosphorylation by specific protein phosphatases. Applicants have designed kinase-inducible domains based on a modular architecture, which allows kinase-inducible domains to be responsive to any specific serine-threonine kinases. Kinase-inducible domains can consist of canonical amino acids, allowing their use as expressible tags of protein kinase activity.01-12-2012
201200103935'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.01-12-2012
20120022244SELF-ASSEMBLED POLYNUCLEOTIDE STRUCTURE - The present application provides polynucleotide structures such as nucleic acid ribbons and nucleic acid tubes, methods for making the polynucleotide structures, and methods for making two-dimensional or three-dimensional objects comprising the nucleic acid ribbons and nucleic acid tubes.01-26-2012
20120071640Sulfurizing reagents and their use for oligonucleotides synthesis - An oligonucleotide which comprises at least one internucleotide linkage comprising a P—S—R bond and at least two nucleosides, wherein R corresponds to the formula (I)03-22-2012
20110092687STABLE LYSIS BUFFER MIXTURE FOR EXTRACTING NUCLEIC ACIDS - The invention relates to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. The invention relates to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives.04-21-2011
20110092686MULTICAPILLARY SAMPLE PREPARATION DEVICES AND METHODS FOR PROCESSING ANALYTES - Disclosed herein are sample preparation devices, such as pipette tips and pipette tip extenders, for example, useful for associating and releasing analytes.04-21-2011
20110092685AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID - To provide an excellent amidite for synthesizing modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid, and a method for synthesizing modified nucleic acid using the amidite. Specifically, an amidite for synthesizing modified nucleic acid, expressed by General Formula (I):04-21-2011
20120071639Methods and compositions of nucleic acid ligands for detection of foodborne and waterborne pathogens - Specific DNA sequences for binding various foodborne and waterborne pathogens and biotoxins are described. Each of these sequences can function in varying assay and sensor formats with varying degrees of success.03-22-2012
20120157670Aptamer-based assays - We describe examples using aptamers for capturing and reporting the presence of a target, such as a pathogen. Examples described here include a set of aptamers that are specific to 06-21-2012
20110065907Methods and compositions for labeling nucleic acids - The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. In particular, the methods include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.03-17-2011
20110065906COMPOSITIONS AND METHODS FOR RECOVERY OF NUCLEIC ACIDS OR PROTEINS FROM TISSUE SAMPLES FIXED IN CYTOLOGY MEDIA - The present invention provides compositions and methods for improving nucleic acid or protein recovery from fixed biological samples.03-17-2011
20110105740SOLUBLE TNF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.05-05-2011
20110105739NOVEL MATRIX MATERIALS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF IN METHODS FOR ISOLATING BIOMOLECULES - The invention relates to functionalized matrix materials or matrices that have structures of general formula (I) T-(C═O)O—B-D, methods for the production thereof, and the use thereof in methods for purifying and isolating biomolecules.05-05-2011
20120123106METHOD FOR ISOLATING HIGH-PURITY RNA BY MEANS OF PARAMAGNETIC MICROPARTICLES AND NANOPARTICLES - The invention relates to a purification method for high-purity, DNA-free RNA using a mixture of nanocarrier beads and paramagnetic beads.05-17-2012
20120123105Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer - A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. Another embodiment is a method to determine relapse free potential in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and a 24-gene signature, and developing a quantitative expression profile.05-17-2012
20100093986METHODS OF DIRECT GENOMIC SELECTION USING HIGH DENSITY OLIGONUCLEOTIDE MICROARRAYS - The present disclosure encompasses methods (hereinafter termed ‘Microarray-based Genomic Selection’ (MGS), capable of isolating user-defined unique genomic sequences from complex eukaryotic genomes.04-15-2010
20120149889Methods and compositions of DNA ligands for arthropod-borne pathogen detectionand prophylaxis or therapy - Specific DNA ligand sequences for binding various arthropod-borne pathogens including arboviruses, rickettsia and parasites are described. Each of these sequences or their linear, two- and three-dimesional linked sequences can function in varying assay and sensor formats with varying degrees of success. Linkage of the whole or partial DNA sequences (putative binding sites) can be used to enhance specificity and affinity towards complex targets, thereby improving assay selectivity and sensitivity in many instances. In addition, the DNA sequences may bind and neutralize or prevent infection from arthropod-borne viruses, rickettsia and Leishmania or other parasites.06-14-2012
20120149888SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS - The present invention relates to synthesis, purification and methods to obtain high purity novel 2′-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units into defined sequence synthetic DNA and RNA. Various synthetic oligonucleotides, such as HIV integrase inhibitor 14-mer and thrombin binding oligonucleotide, thrombin-1, bearing ara-2′-omethyl modification have been synthesized. It is anticipated the oligonucleotides incorporating these monomers will exhibit biological activities related to antisense approach approach, design of better SiRNA's, diagnostic agents. Similarly, it is anticipated that oligonucleotides incorporating such novel nucleosides will be useful to develop therapeutic candidates designing stable G-quadruplexes and Aptamers for oligonucleotide structure, folding topology, evaluation of biochemical properties and design and develop as therapeutic agents. It is further anticipated that the nucleosides, phosphates and triphosphates of this invention could develop as therapeutic agents.06-14-2012
20110184161USE OF MICROARRAYS FOR GENOMIC REPRESENTATION SELECTION - The present invention provides novel methods for reducing the complexity of a genomic sample for further analysis such as direct DNA sequencing, resequencing or SNP calling. The methods use pre-selected immobilized oligonucleotide probes to capture target nucleic acid molecules from a sample containing denatured, fragmented genomic nucleic acid. The disclosed method provides for cost-effective, flexible and rapid enrichment of target nucleic acid from complex biological samples.07-28-2011
20110184160NUCLEIC ACID MOLECULE ENCODING CONSENSUS INFLUENZA A HEMAGGLUTININ H1 - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided.07-28-2011
20110118455PROTECTING GROUP FOR INDOLE GROUP, NUCLEIC ACID-SYNTHESIZING AMIDITE AND NUCLEIC ACID-SYNTHESIZING METHOD - A protecting group for 1-nitrogen atom of an indole group including a sulfonylethyl carbamate group, wherein the protecting group is represented by the following General Formula (I) and capable of being removed from the 1-nitrogen atom of the indole group in an aprotic solvent:05-19-2011
20120136143Methods and Kits for Sense RNA Synthesis - Methods and kits are provided for performing multiple rounds of sense RNA synthesis. The sense RNA molecules can be used in various research and diagnostic applications, such as gene expression studies involving nucleic acid microarrays.05-31-2012
20120172581PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER - Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.07-05-2012
20100056768HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES - The present invention is directed to RNA oligonucleotides or complexes of RNA oligonucleotides, denoted herein together as RNA complexes, containing at least one, but optionally more that one, hydroxymethyl substituted nucleotide monomer(s). By a hydroxymethyl substituted nucleotide monomer is understood a nucleotide monomer containing a hydroxymethyl group (that may be unsubstituted, O-substituted for example with a conjugating group, or converted into an optionally substituted or conjugated aminomethyl group). This hydroxymethyl group is not partaking in formation of an internucleotide linkage and is not the hydroxymethyl group (containing the 5′-hydroxy group) of a natural RNA monomer. The RNA complexes of the invention may be useful for therapeutic applications, diagnostic applications or research applications. The complexes include short interfering RNA complexes (siRNA duplexes) comprising an antisense strand and a continued or a discontinued passenger strand (“sense strand”) capable of regulating gene expression. At least one of these strands, possible more than one of these strands, are modified with one or more hydroxymethyl substituted nucleotide monomer(s) of this invention, that can be positioned at the 3′-end, at the 5′-end or internally. The RNA complexes of the invention can also be single stranded RNA oligonucleotides (“RNA strands”) that are modified with at least one, but optionally more that one, hydroxymethyl substituted nucleotide monomer(s). Such single stranded RNA strands are to be considered included whenever the term RNA complexes is used in this patent application. The complexes of the invention display enhanced stability towards nucleolytic degradation relative to the corresponding complexes comprised entirely from natural RNA monomers.03-04-2010
20120316326DNA APTAMER SPECIFICALLY BINDING TO HUMAN CARDIAC TROPONIN I - Disclosed are a DNA aptamer specifically binding to human cardiac troponin I, and a composition and a diagnostic kit for the diagnosis of acute cardiovascular diseases, comprising the same. Being superior in specificity and stability to antibodies which are conventionally used to diagnose acute cardiovascular diseases, the DNA aptamers specifically binding to human cardiac troponin I can be developed into biosensors which determine human cardiac troponin I levels with high sensitivity and accuracy, greatly contributing to the diagnosis in an early stage of acute cardiovascular diseases. It is expected to lots of help for increase of diagnostic accuracy.12-13-2012
20100048883METHOD FOR PURIFYING RNA ON A PREPARATIVE SCALE BY MEANS OF HPLC - The application describes a method for the preparative purification of RNA, which method is distinguished in that the RNA is purified by means of HPLC using a porous reversed phase as the stationary phase. The use of the porous reversed phase in this HPLC method is also described.02-25-2010
20100298551Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage.11-25-2010
20120178917RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.07-12-2012
20090088560Process for Nucleic Acid Purification - This invention provides a method of isolating and purifying nucleic acid using a binding buffer comprising a sodium- or potassium-ion-containing solution with the final concentrations of either sodium- or potassium-ion concentration of at least about 500 mM, preferably greater than about 1 M to saturate, and the pH of such solution of being adjusted in the range of about 2.0 to 5.0, for reversible binding of the nucleic acid to a silicon-containing matrix. The invention further provides a method of increasing reversible binding of the nucleic acid to a silicon-containing matrix using the binding buffer of the invention in addition to 20% to 50% (v/v) of a water-soluble organic solvent, e.g., ethanol. Nucleic acid obtained thereof that is free of chaotropes and other toxic chemicals, and nucleic acid purification kits comprising the binding buffer of the invention are also provided.04-02-2009
20100292451METHOD FOR DIAGNOSING SELECTED ADENOCARCINOMAS - A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.11-18-2010
20120316325DNA APTAMER SPECIFICALLY BINDING TO pLDH (PLASMODIUM LACTATE DEHYDROGENASE) - Disclosed herein are a DNA aptamer specifically binding to pLDH (12-13-2012
20120259104SELF-AMPLIFYING FOLDED OLIGONUCLEOTIDE STRUCTURE - The present invention relates to a self-amplifying folded oligonucleotide structure for sensitive oligonucleotide sensing without polymerase chain reaction (PCR). A self-amplifying folded oligonucleotide structure comprise a target sensing sequence having stem loop structure, a signaling molecule and signal modifying molecule labeled two stems wherein the two stems include oligonucleotide sequence that is complementary to a target sensing sequence of another self-amplifying folded oligonucleotide structure.10-11-2012
20120238738Oligonucleotide Adapters: Compositions and Methods of Use - Compositions are provided that include a synthetic oligonucleotide characterized by a double-stranded region, a single-stranded region, a forward primer site, a reverse primer site and one or more cleavage sites therebetween. Methods of use for these compositions include adaptors for the amplification of DNA fragments.09-20-2012
20120238737THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS - Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, dithiocarbonate groups, as well as thionocarbamate protecting groups. Aspects of the invention further include nucleic acids that include the protecting groups of the invention, as well as methods of synthesizing nucleic acids using the protecting groups of the invention.09-20-2012
20120238736DEVICE FOR SHEARING NUCLEIC ACIDS AND PARTICULATES - Disclosed herein is a device for shearing nucleic acids and particulates in a syringe or vial comprising an ultrasonic transducer attached to a solid cylindrical horn comprising a tip shaped to engage the profile of the tip of a syringe or vial. The horn tuned for maximum amplitude vibration at its tip.09-20-2012
20120190835HYBRIDIZATION CHAIN REACTION AMPLIFICATION FOR IN SITU IMAGING - The present invention relates to the use of fluorescently labeled nucleic acid probes to identify and image analytes in a biological sample. In the preferred embodiments, a probe is provided that comprises a target region able to specifically bind an analyte of interest and an initiator region that is able to initiate polymerization of nucleic acid monomers. After contacting a sample with the probe, labeled monomers are provided that form a tethered polymer. Triggered probes and self-quenching monomers can be used to provide active background suppression.07-26-2012
20120190834APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THEREAPEUTICS - The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.07-26-2012
20080300394DEFECTIVE SINDBIS VIRAL VECTORS - Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.12-04-2008
20120264926Orthogonal Q-Ribosomes - The invention relates to 16S rRNA comprising a mutation at A1196, and to 16S rRNA further comprising a mutation at C1195 and/or A1197, and to 16S rRNA which comprises (i) C1195A and A1196G; or (ii) C1195T, A1196G and A1197G; or (iii) A1196G and A1197G. The invention also relates to ribosomes comprising such 16S rRNAs and to use of same.10-18-2012
20120322991Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types - The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.12-20-2012
20110224415HUMAN MUTY - A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.09-15-2011
20110237786METHOD FOR PREPARING OLIGONUCLEOTIDE - A method for preparing oligonucleotide comprising reacting the compound of Formula (1) with the compound of Formula (2) in a liquid reaction medium under the condition of condensation reaction to obtain the compound of formula (3). In the method according to the present invention, the functional groups are protected by suitable protective groups to only expose the 5′-OH of the compound of Formula (1) (OH-component) and the 3′-phosphate of the compound of Formula (2) (P-component) which are to be connected, so that the condensation reaction is carried out in a liquid reaction medium to bond the OH-component and P-component to obtain DNA or RNA short chain. The method of the present invention does not need a solid phase column and can be carried out in a liquid reaction medium. Thus, oligonucleotides can be synthesized on a large scale.09-29-2011
20110160443RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.06-30-2011
20110319606COMPOUNDS AND METHODS FOR LABELING OLIGONUCLEOTIDES - A compound having the general formula shown below:12-29-2011
20110319605PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN IMMOBILIZED OLIGONUCLEOTIDE - Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.12-29-2011
20100063263Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use - The invention relates to magnetic particles coated with silica (Si02), whereby the silicate layer is closed and tight and is characterized by having an extremely small thickness on the scale of a few nanometers—hereafter also referred to as a silica nanolayer. This invention also relates to an improved method for producing these silicate-containing magnetic particles that, in comparison to the prior art, lead to a product having a closed silicate layer and thus entail a highly improved purity. In addition, the novel method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface, thereby having a positive influence on the properties and biological applications cited below. The novel method also enables the depletion of nanoparticulate solid substance particles on the basis of a fractionated centrifugation. The inventive magnetic particles exhibit an optimized magnetization and suspension behavior as well as a very advantageous run-off behavior from plastic surfaces. These highly pure magnetic particles coated with silicon dioxide are preferably used for isolating nucleic acids from cell and tissue samples, whereby the separating out from a sample matrix ensues by means of magnetic fields. These particles are particularly well suited for the automatic purification of nucleic acids, mostly from biological body samples for the purpose of analyzing them with different amplification methods.03-11-2010
20120101267MULTICOMPONENT NUCLEIC ACID ENZYMES WITH CLEAVAGE, LIGASE OR OTHER ACTIVITY AND METHODS FOR THEIR USE - The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure which may have cleavage, ligase or other enzymatic activity. Compositions for making MNAzymes and collections of MNAzymes are provided, together with uses thereof. Also provided are methods for using MNAzymes for the detection, identification and/or quantification of one or more targets. The methods can be practiced in solution-based assays or in assays where one or more reaction components are attached to a support structure. The methods allow for multiplexing the MNAzyme detection to detect multiple targets in a single reaction. Also provided are kits for making the compositions, and for practicing the methods provided herein.04-26-2012
20130023655METHOD FOR PRECIPITATING ANIONIC SURFACTANT IONS IN THE PRESENCE OF NUCLEIC ACIDS - The present invention relates to a method for selectively precipitating anionic surfactant ions from a liquid sample comprising anionic surfactant ions and nucleic acids, as well as to a kit for the isolation and purification of nucleic acids.01-24-2013
20080249291Oligonucleotides Derived From Mycobacterium for Stimulating Immune Function, Treating Immune-Related Diseases, Atopic Dermatitis and/or Protecting Normal Immune Cell - Disclosed are oligonucleotides for manipulating an immune reaction. The oligonucleotides of the present invention may be useful to stimulate the immune function, to treat the immune-related diseases and the atopic dermatitis, or to protect the normal immune cells.10-09-2008
20080227965Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers - The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.09-18-2008
20110263838MULTICAPILLARY DEVICE FOR SAMPLE PREPARATION - A multicapillary sample preparation device, especially useful for handling biological samples, comprising a plurality of uniform capillary tubes coated with a stationary phase, and arranged in a monolithic element. The multicapillary device is suitable for attachment to a pipette, micropipette, syringe, or other analytical or sample preparation instrument.10-27-2011
20130178611Novel Nucleic Acid Having Adjuvanticity and Use Thereof - The disclosed nucleic acid at least containing a single-stranded DNA to be delivered to endosomes of dendritic cells and a double-stranded RNA capable of activating TLR3 can be delivered to endosomal TLR3 and has a strong adjuvanticity with few side effects, and therefore is useful as an active ingredient of immunostimulants, vaccine adjuvants, cancer therapeutic agents and the like.07-11-2013
20130178612CHIRAL AUXILIARIES - Chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity, and compounds represented by the following the general formula (I) or the general formula (XI) for introducing the chiral auxiliaries.07-11-2013
20130178610OLIGONUCLEOTIDE SPECIFIC UPTAKE OF NANOCONJUGATES - The present invention concerns nanoparticles functionalized with an oligonucleotide and a domain for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a nanoparticle that is taken up by a cell at an efficiency different than a nanoparticle functionalized with the same oligonucleotide but does not contain a domain.07-11-2013
20080221315NUCLEIC ACID-BASED TRANSLATION SYSTEM AND METHOD FOR DECODING NUCLEIC ACID ENCRYPTED MESSAGE - A nucleic acid-based translation system where the components of a nucleic acid multicrossover molecule serve as message, translation device and part of the translated product. One continuous strand of a nucleic acid multicrossover molecule acts as a message, which nucleic acid crossover strands, functioning together as a translation device, translate into nucleic acid product strands. Organic molecules appended to the backbone of the nucleic acid product strands can also be polymerized to form a polymer sequence of appended organic molecules.09-11-2008
20120253026Expanding the Eukaryotic Genetic Code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.10-04-2012
20130123481MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF - The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.05-16-2013
20130123480Multicomponent Nucleic Acid Enzymes And Methods For Their Use - The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure. Compositions for making MNAzymes, and collections of MNAzymes are provided. Also provided are methods for using MNAzymes for the detection, identification and/or quantification of one or more targets. The methods can be practiced in solution-based assays or in assays where one or more reaction components are attached to a support structure. The methods allow for multiplexing the MNAzyme detection to detect multiple targets in a single reaction. Also provided are kits for making the compositions, and for practicing the methods provided herein.05-16-2013
20130144047FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations.06-06-2013
20110218332Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof - The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question function as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human ob polypeptides are provided.09-08-2011
20080200661COMPOSITION FOR IN VIVO DELIVERY - The present invention relates to the delivery of desired compounds (e.g., nucleic acids) into cells using releasable delivery systems which include complexing nucleic acids and delivery ligands.08-21-2008
20080200660Method for the hydrophobisation of DNA molecules - The present invention relates to a method for the hydrophobisation of DNA molecules comprising mixing an aqueous solution of the DNA molecule with a solution of a cationic lipid or a surfactant in an organic solvent under agitation for a period in the range of 30 to 60 minutes to obtain the hydrophobic DNA in organic phase.08-21-2008
20110213135Cytotoxic Nucleotides for Targeted Therapeutics - The present invention provides a method of generating a nucleic acid, which specifically binds to an extracellular surface protein expressed by a cell of interest, and which nucleic acid comprises a compound of interest to be delivered to the cell of interest.09-01-2011
20110313143NUCLEIC ACID PURIFICATION APPARATUS AND METHOD - Provided herein is a clarification/binding device for the isolation of at least one target molecule from a sample. The clarification/binding device can comprise an clarification column and a binding column. The clarification column can be configured to receive the sample. Further, the clarification column can comprise a filter configured to filter at least one non-target molecule from the sample. The binding column can be configured to receive the filtered sample from the clarification column. The binding column can comprise a binding material for binding at least one target molecule. The clarification/binding device can be configured to filter the sample and bind at least one target molecule under negative pressure. Further provided herein is an apparatus for the isolation of a target molecule from a sample. The apparatus can comprise a top plate and a vacuum manifold comprising a first chamber and a second chamber. The top plate can be configured to be used with one or both of the first vacuum chamber and the second chamber of the vacuum manifold. Further provided herein are methods of use of the clarification/binding device and the vacuum apparatus and kits comprising the clarification/binding device and vacuum apparatus.12-22-2011
20100286382DISPOSABLE LABORATORY IMPLEMENT - A method of processing a liquid sample containing an initial quantity of nucleic acids that involves providing a plastic, disposable laboratory implement having at least one transparent wall segment made of a polypropylene mixed with an amount of a clarifier additive that is at least twice as high as is necessary to obtain transparency in the polypropylene, wherein the transparent wall segment exhibits a surface gloss greater than 160 as measured per DIN 67530 at an angle of 60°, bringing the liquid sample into contact with the at least one transparent wall segment and removing the liquid sample from the at least transparent wall segment, wherein the nucleic acid adsorption ratio for the transparent wall segment is less than 3 (wt/wt) relative to relative to the initial quantity of nucleic acids in the liquid sample.11-11-2010
20100286381DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED IN THE DETECTION OF THE DELETION OF G-CSF EXON 3 - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.11-11-2010
20100286379BISULPHITE TREATMENT OF RNA - The invention relates to a method for bisulphite treating RNA comprising reacting RNA with a bisulphite reagent at 50-90° C. for 5-180 minutes so as to form treated RNA and recovering the treated RNA.11-11-2010
20100286378Composition of Asymmetric RNA Duplex As MicroRNA Mimetic or Inhibitor - The present invention provides double-stranded RNA molecules that are asymmetrical in strand length. The RNA molecule of the invention, the asymmetric RNA duplex, has one or two overhangs at the end. In one aspect, these novel RNA duplex molecules serve as effective mimetics of miRNA. In another aspect, they are designed to function as effective inhibitors of miRNA. Accordingly, the RNA molecules of the present invention can be used to modulate miRNA pathway activities, with tremendous implications for research, drug discovery and development, and treatment of human diseases.11-11-2010
20110251382ISOLATION OF NUCLEIC ACID - The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be couple with a further step to isolate RNA from the same sample.10-13-2011
201102757945-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same.11-10-2011
20110275793Chemical RNA Synthesis Method - The invention relates to a method for the chemical synthesis of RNA, comprising the following steps: a) bonding to a solid support of a monomer having formula (II) in which—X11-10-2011
20100292452Modified nucleotides - The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′)2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H.11-18-2010
20100317839TP EXPRESSION-INHIBITING COMPOUND AND SIRNA SEQUENCE THEREOF - The present invention discloses a TP expression-inhibiting compound and a TP expression-inhibiting siRNA sequence, wherein a siRNA sequence partially or completely complementary to the sequence of TP is used to inhibit TP expression, whereby is effectively reduced the survival rate of cancer cells in an anoxic environment.12-16-2010
20130184446MICROORGANISM NUCLEIC ACID PURIFICATION FROM HOST SAMPLES - The present disclosure provides systems, devices, and methods for purifying microorganism nucleic acid from a host sample, such as a whole blood sample from a human. In certain embodiments, devices and systems with multiple filters are employed and provide for the selective removal of blood cells and host nucleic acids from a sample in order to enrich for microorganism nucleic acid.07-18-2013
20130158243PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES - The present invention provides processes for the conjugation of NHS esters to amino-modified oligonucleotides. The processes provide the amino-modified oligonucleotide on a solid support such that conjugation can be carried out under conditions that can accommodate a wide variety of NHS esters and oligonucleotides.06-20-2013
20130158244Modular Functional Peptides for the Intracellular Delivery of Nanoparticles - Described are nucleic acids encoding a polypeptide for delivery of a nanoparticle to the cytosol, the peptide comprising: (a) a nanoparticle association domain, (b) a spacer domain, (c) an uptake domain, and (d) a vesicle escape domain, wherein the domains (a) through (d) appear in the same order as listed above, and wherein the peptide, upon addition of a non-hydrolyzable lipophilic moiety to the vesicle escape domain and binding to a nanoparticle, is effective to induce uptake of a nanoparticle by a cell and delivery of the nanoparticle to the cytosol of the cell. Also described are methods of delivery of a nanoparticle to the cytosol of a cell, the method comprising providing to a cell a nanoparticle attached to such a peptide. Exemplary nanoparticles include quantum dots.06-20-2013
20130184447METAL COORDINATED COMPOSITIONS - A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.07-18-2013
20130123479Soluble TNF Receptors and Their Use in Treatment of Disease - The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.05-16-2013
20130123478METHODS OF PREPARING TARGETED APTAMER PRODRUGS - The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonucleotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells.05-16-2013
20120022243BIOMOLECULAR SELF-ASSEMBLY - The present invention relates generally to programming of biomolecular self-assembly pathways and related methods and constructs for self-assembly of prescribed two and three-dimensional structures.01-26-2012
20130197206METHOD FOR ACQUISITION OF SMALL RNA - The purpose of the present invention is to provide a method which is applicable to high throughput and by which small RNA can be obtained simply and efficiently. The present invention relates to a method for acquisition of small RNA, comprising contacting a carrier, in which a substance having affinity to small RNA-binding protein is immobilized on its surface, with a complex of the small RNA-binding protein and a small RNA (protein-RNA complex) to bind the protein-RNA complex to the aforementioned carrier, and releasing the small RNA by heating the carrier bound with the aforementioned protein-RNA complex at 70° C. to 100° C. in water or buffer solution of pH 3.0 to pH 8.008-01-2013
20120095200COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY NUCLEIC ACID CONTAINING A DICER SUBSTRATE AND A RECEPTOR BINDING REGION - The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in a eukaryotic cell, involving contacting a cell with an isolated nucleic acid containing a Dicer substrate and a receptor binding region in an amount effective to reduce expression of a target gene in a cell.04-19-2012

Patent applications in class DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)

Patent applications in all subclasses DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)